90/012,6572-(N-METHYL-PROPANAMINE)-3-(2-NAPHTHOL)THIOPHENE, AN IMPURITY OF DULOXETINE HYDROCHLORIDE7,759,500Closed

Status

Reexamination Certificate Issued

Filed

Nov 8, 2012

Last Updated

Aug 23, 2013

Art Unit

3991

Requester

Unknown

Requester Law Firm

Kelley Drye & Warren, LLP

Requested By

Third Party

Patent OwnerInferred

Teva Pharmaceuticals USA Inc.

Sector (CPC)

CChemistry & Materials
C07Organic Chemistry
C07DHeterocyclic Compounds

USPC

549Organic Compounds

Reexam History (25 events)

Aug 23, 2013REEXInput Issue Number and Issue Date for Reexamination
Aug 14, 2013RXPUBSReexam Forwarded to Office of Publications
Aug 9, 2013MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Jul 31, 2013RXLITSRReexam Litigation Search Conducted
Jul 10, 2013RXFWDXDate Forwarded to Examiner
May 9, 2013MR.NFRX - Mail Reexam Non-Final Action
Mar 19, 2013RXFWDXDate Forwarded to Examiner
Feb 12, 2013NRX.Notice of Reexam Published in Official Gazette
Feb 7, 2013WIDSInformation Disclosure Statement (IDS) Filed
Feb 7, 2013IDSCInformation Disclosure Statement considered
Jan 17, 2013MREXORX - Mail Ex Parte Request for Reexamination Granted
Nov 19, 2012MREXNRX - Mail Examiner Interview Summary Record
Nov 13, 2012DOCKCase Docketed to Examiner in GAU
Nov 9, 2012RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Nov 9, 2012RXNREQFDNotice of reexamination request filing date
Nov 9, 2012RXNREQAUNotice of assignment of reexamination request
Nov 9, 2012RXLITSRReexam Litigation Search Conducted
Nov 9, 2012MRXNReexamination Formalities Notice Mailed
Nov 9, 2012MRXNReexamination Formalities Notice Mailed
Nov 8, 2012RXOSUCOrig Req Receipt Corrected
Nov 8, 2012RXC/SRCertificate of Service
Oct 10, 2012MRICRRX - Mail Notice of Incomplete Ex Parte Reexam Request
Oct 9, 2012RXTTLRPTTitle Report
Sep 14, 2012RXOSUB.RReexamination requested by third party requester
Sep 14, 2012RXOSUBReceipt of Original Ex Parte Reexam Request

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

None found

Prosecution History

None found

Maintenance Fees

Grant
Jul 20, 2010
3.5-yr
Jan 20, 2014
7.5-yr
Jan 20, 2018
11.5-yr
Jan 20, 2022
Expiry
Nov 20, 2028

Entity Status

Large Entity

Expires

Nov 20, 2028 (2.7 yr remaining)

Term Adjustment

+716 days (~2.0 yr)

Other

USPTO Event: Expire Patent

Assignments

Jan 2007Feb 2007Mar 2007FiledALEXEI PLOUTNOOSNAT PORTER-KLEKSSANTIAGO INIMILI ABRAMOVDINA BEREZOVSKYANITA LIBERMANTEVA PHARMACEUTICAL INDUSTRIES LTD.TEVA PHARMACEUTICALS USA, INC.
AssignmentReel/Frame: 019340/0788Recorded: May 24, 2007

From

MILI ABRAMOVInventor
Feb 20, 2007
DINA BEREZOVSKYInventor
Feb 22, 2007
SANTIAGO INIInventor
Feb 18, 2007
ANITA LIBERMANInventor
Mar 19, 2007
ALEXEI PLOUTNOInventor
Feb 15, 2007
OSNAT PORTER-KLEKSInventor
Feb 15, 2007

To

TEVA PHARMACEUTICAL INDUSTRIES LTD.

AssignmentReel/Frame: 019156/0123Recorded: Apr 11, 2007

From

MILI ABRAMOVInventor
Feb 20, 2007
DINA BEREZOVSKYInventor
Feb 22, 2007
SANTIAGO INIInventor
Feb 18, 2007
ALEXEI PLOUTNOInventor
Feb 19, 2007
OSNAT PORTER-KLEKSInventor
Feb 15, 2007

To

TEVA PHARMACEUTICAL INDUSTRIES LTD.

AssignmentReel/Frame: 019156/0289Recorded: Apr 11, 2007

From

TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 27, 2007

To

TEVA PHARMACEUTICALS USA, INC.